Studies including mixed populations of patients with BC in relation to the tumor subtype (mostly TNBC in the early setting), showed that higher PD-L1 expression in BC is generally associated with longer OS in early disease [50–54], higher pCR rate after neoadjuvant treatment and better EFS [53, 55, 56]. This evidence concerns the gene CD274 and breast cancer.